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2Abstract
Objective: To investigate the relationship between NF-B activity, cytokine levels, and pain 
sensitivities in a rodent model of osteoarthritis (OA). 
Method:  OA was induced in transgenic NF-κB luciferase reporter mice via mono-iodoacetate 
(MIA) intra-articular injection.  Using luminescent imaging we evaluated the temporal kinetics 
of NF-B activity and its relationship to the development of pain sensitivities and serum 
cytokine levels in this model.
Results: MIA induced a transient increase in joint-related NF-кB activity at early time points 
(day 3 post-injection) and an associated biphasic pain (mechanical allodynia) response.   NF-кB 
activity, serum IL-6, IL-1β, and IL-10 accounted for ~75% of the variability in pain-related 
mechanical sensitivities in this model.  Specifically, NF-кB activity was strongly correlated to 
mechanical allodynia and serum IL-6 levels in the inflammatory pain phase of this model (day 
3), while serum IL-1β was strongly correlated to pain sensitivities in the chronic pain phase of 
the model (day 28).
Conclusion: Our findings suggest that NF-кB activity, IL-6 and IL-1β may be playing distinct 
roles in pain sensitivity development in this model of arthritis and may act to distinguish the 
acute from chronic pain phases of this model.  This work establishes luminescent imaging of NF-
кB activity as a novel imaging biomarker of pain sensitivities in this model of OA.
3Introduction
Knee osteoarthritis (OA) is a leading cause of disability with large associated economic costs. It 
is anticipated that 20% of adults will be affected by pain or disability associated with OA by the 
year 2030 (1).  At the tissue level, the disease is associated with cartilage degradation, synovial 
hypertrophy, and subchondral bone remodeling.  Clinically, the disease is diagnosed by 
radiographic changes that include joint space narrowing, presence of osteophytes, and synovial 
hypertrophy.  While patients present with joint pain and impaired joint mobility (2), the 
mechanistic link between these behaviors and tissue level changes are poorly understood (3-5).   
Direct or indirect interactions of inflammatory cytokines (e.g. TNF-α, IL-1β, IL-6) with knee 
joint afferents has been suggested as a possible contributor to pain in arthritis (6).   The 
inflammatory cytokines TNF-α and IL-6 have been demonstrated to play a direct role in 
sensitization of nociceptors and the development of mechanical allodynia in preclinical models 
of inflammatory arthritis (7, 8). Elevated levels of these pro-inflammatory cytokines have been 
observed in human OA patients (6, 9, 10), while TNF-α and IL-1β antagonism may lead to 
substantial reductions in pain scores for patients presenting with an inflammatory component of 
osteoarthritis (11-13).   While the presentation of inflammation may vary widely across patients 
with OA and even within the time course of OA pathology, it is now thought that inflammatory 
cytokines play a key role in pain development in OA.  
A key regulator of TNF-α, IL-1β, and IL-6 is the transcription factor nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB).  The NF-кB transcription factor family induces the 
expression of more than 150 genes that play a role in immunity, inflammation, anti-apotosis, cell 
4proliferation, and the negative feedback of NF-кB (14-17). NF-кB activity can be induced by 
multiple cellular stimuli including inflammatory cytokines (e.g. TNF-α and IL-1β), extracellular 
matrix degradation products, and mechanical overload.  Once activated, NF-кB induces target 
gene expression in multiple cell types including synoviocytes, chondrocytes, and fibroblasts (18-
20).  In arthritis, NF-кB activity is associated with increased expression of pro-inflammatory 
cytokines (IL-1β, TNF-α, IL-6), metalloproteinases, chemokines, and inducible enzymes (COX-
2) (21-24). Although its role in pain in arthritis is not completely understood, the inhibition of 
key mediators of the NF-κB activation pathway leads to a reduction in pain in rodent models of 
arthritis (25, 26), suggesting that regulation of these key mediators is the means by which NF-кB 
facilitates the development and propagation of pain in arthritis.
Carlsen and co-workers previously described the use of a transgenic NF-кB-luciferase reporter 
mouse to study the transient kinetics of NF-кB activation after UVB radiation exposure and 
collagen-antibody induced arthritis (17, 27).  This transgenic mouse contains NF-кB response 
elements upstream of the firefly luciferase gene, which allows NF-кB activity to be non-
invasively and longitudinally quantified via luminescent imaging; this has been used to 
demonstrate NF-кB inhibition using a small molecule inhibitor of IKK-2 in a model of collagen 
antibody-induced arthritis (28).  
For its repeatability and rapid onset of pathology, intra-articular injection of mono-iodoacetate 
(MIA) has been widely used to induce arthritis (26, 29-37).  Injection of MIA into the joint 
inhibits glycolysis in chondrocytes, which results in chondrocyte cell death.  As a result, changes 
resembling human OA that include proteoglycan loss, collagen fibrillation, and subchondral 
5bone remodeling, progress rapidly over a 4-6 week period (29-34, 37, 38). A biphasic pain 
response has been documented in the MIA model that includes an early inflammation-associated 
pain phase followed by a late non-inflammatory pain phase (36, 37).  The MIA model is of great 
interest for studying the transient role of NF-кB activity and cytokine levels in contributing to 
both inflammatory and non-inflammatory pain in a model of OA.
In the present study, in vivo luminescent imaging of NF-кB activity was used to investigate the 
relationship between NF-кB activity, serum cytokines, and pain sensitivities in the rodent model 
of MIA-induced OA.  This model was evaluated to test whether in vivo luminescent imaging 
could provide a spatially accurate measure of NF-кB activity in the knee joint and to test its 
relationship to development of disease.  
Method
Intra-articular Injections and Experimental Timeline
The transgenic mice used for this study were engineered to carry cDNA for firefly luciferase 
downstream of NF-kB response elements (n=24, BALB/c-Tg(NFκB-RE-luc), age 7-8 weeks; 
Taconic Farms Inc., Hudson, NY). All procedures were performed with approval of the Duke 
University IACUC.  Following a 1-week acclimation period, under anesthesia (2% isoflurane 
inhalation), mice received intra-articular knee injections via 30-gauge needle of MIA (5 μl, 10 
mg/ml, n=12) or saline as a control (5 μl, n=12).  One set of animals (n=6/group, Saline and 
MIA) was sacrificed on day 3 and a second set of animals was sacrificed on day 28 (n=6/group, 
Saline and MIA).  Time points of sacrifice were selected to coincide with the early (day 3) and 
6late (day 28) pain phases observed in the MIA model.   Prior to sacrifice, animals underwent in 
vivo luminescent imaging to quantify NF-B activity pre-MIA injection and on days 1, 3, 7, 14, 
21, and 28 post-MIA injection.  Mice underwent testing to measure mechanical allodynia and 
relative weight-bearing at these same time points.  In a subset of animals, organs and relevant 
tissues were harvested for ex vivo imaging immediately after sacrifice. Serum was obtained from
all animals at sacrifice (day 3 or day 28) via cardiac puncture to assay for a subset of systemic 
pro- and anti- inflammatory cytokines. 
In Vivo NF-B Activity Luminescent Imaging
At each imaging time point, mice were anesthetized and injected with D-luciferin prior to 
imaging (150 mg/kg i.p., Caliper Life Sciences Inc., Hopkinton, MA).  After 10 minutes to allow 
D-luciferin distribution, whole-body imaging of luminescence arising from NF-κB activity was 
performed on an in vivo imaging system (IVIS 100, Perkin Elmer, Waltham, Massachusetts) with 
a 15 second exposure; determined from preliminary studies to avoid saturation of pixels in all 
images.  
Six cadaveric mice were used to define an appropriate region of interest (ROI) for luminescence 
image analysis.  Radiographs of cadaveric mice were obtained on an In Vivo Imaging System 
(IVIS) FX Pro (Carestream Health Inc., Rochester, NY) using the same positioning as for 
luminescent imaging.  An ROI was selected (4 x 8 mm ellipse) that was anchored to the 
intersection of the ipsilateral hind limb and mouse body (Figure 1A) and encompassed the total 
knee joint of all animals. 
7At each time point, the ROI luminescence (LUMROI) was measured as photons/sec/cm
2
for all 
animals.  Luminescence data for each animal at each time point was normalized to preinjection 
values from the same animal (NLUM) according to equation 1,
(1) N
LUM

LUM
ROI
(LUM
ROI
)
preinjection
.
Ex Vivo NF-B Activity Luminescent Imaging
Immediately post sacrifice, the ipsilateral and contralateral tibiofemoral knee joints, patella, and 
adjacent muscle tissue were harvested for immediate ex vivo luminescent imaging in a subset of 
animals (n=18).  Tissue was placed in separate wells of a 12-well tissue culture plate and each 
well was supplemented with 300 μg/ml D-luciferin in Dulbecco’s Phosphate-Buffered Saline 
(Gibco, Grand Island, New York).  After 5 minutes, the tissue culture plate was imaged as for the 
whole body on the IVIS100 (Perkin Elmer; 15 second exposure).  Selected ROI around each 
tissue was measured as photons/sec/cm
2
(LUMKNEE, LUMPATELLA, LUMMUSCLE).
Pain-related Sensitivity (Mechanical Allodynia)
Mice were acclimated to a wire-bottom cage and exposed to the von Frey testing procedure over 
a period of 3 days prior to the start of the experiment.  Mechanical allodynia was evaluated in the 
ipsilateral hind paw by touching the plantar surface with von Frey filaments (0.07 – 4.0 g; 
Stoelting, Wood Dale, Illinois) using the “up-down” method (39).  Briefly, filaments ranging 
from 0.07 g to 4.0 g were applied to the ipsilateral hind paw for 3-4 seconds, starting with the 0.6 
g filament.  A positive response (paw flick, lick, or vocalization) resulted in moving to the next 
weaker filament, while a lack of response resulted in moving to the next stronger filament.  Data 
8for paw withdrawals following filament application for a minimum of four filaments was used to 
calculate the 50% withdrawal threshold in units of gram-force (50%WT).  Data were collected 
pre-injection and on days 3, 7, 14, 21, and 28 post-injection and normalized to the pre-injection 
levels of the same animal and limb (N50%WT); data are presented as a percentage of the pre-
injection 50%WT according to equation 2,
(2) N
50%WT

50%WT
50%WT
preinjection
100 .
Weight-Bearing
Mouse hind-limb weight-bearing was determined using an incapacitance meter (IITC Life 
Science Inc., Woodland Hills, CA).  Mice were placed in an angled plexiglass chamber with the 
two hind paws resting on two independent force plates, the front paws resting on the plexiglass 
ramp, and the mouse facing forward.  Force (gram-force) readings were obtained over a 3 second 
interval for both the ipsilateral (WBipsi) and contralateral (WBcontr) limb; three independent 
measurements were obtained for each mouse at each time point and averaged.  Percentage 
weight-bearing was normalized (NWB) by dividing the weight-bearing on the ipsilateral limb by 
the total weight-bearing for both hindlimbs according to equation 3,
(3) N
WB

WB
ipsi
WB
ipsi
WB
contr
100 .
Serum Cytokines
The following serum cytokine concentrations were quantified using multiplex and single 
immunoassays (Mouse Pro-inflammatory 7-plex and Mouse MCP-1 single-plex, Meso Scale 
Discovery, Rockville, MD): interleukin-1 beta (IL-1), interleukin-6 (IL-6), interleukin-10 (IL-
910), interleukin-12p70 (IL-12p70), chemokine C-X-C motif ligand 1 (CXCL1), tumor necrosis 
factor-alpha (TNF-), interferon-gamma (IFN-), and monocyte chemotactic protein-1 (MCP-1). 
Measurements were performed on a SECTOR Imager 2400 (Meso Scale Discovery, Rockville, 
MD).  The mean intra-assay CVs for the 7-plex pro-inflammatory and MCP-1 immunoassay 
were 3.3% and 2.8%, respectively. The lower limit of detection (LLOD) for each cytokine is as 
follows: IL-1 (0.21 pg/ml), IL-6 (3.07 pg/ml), IL-10 (0.37 pg/ml), IL-12p70 (9.73 pg/ml), 
CXCL1 (0.27 pg/ml), TNF- (0.63 pg/ml), IFN- (0.06 pg/ml), and MCP-1 (1.46 pg/ml).  One 
half of the LLOD was used for any value below the level of detection for the purpose of 
performing statistical analyses.  Concentrations of serum TNF- and IL-12p70 were below the 
LLOD in a majority of samples and so were not included in the analysis. 
Histology
Both ipsilateral and contralateral limbs were dissected to remove excess skin and musculature 
while preserving the knee joint capsule.  The intact joints were fixed in 10% formalin for 3 days, 
decalcified for 5 days in Cal-EX Decalcifying Solution (Fisher Scientific, Hampton, NH), and 
embedded in paraffin.  Sections (8 μm thick) were taken in the coronal plane within the load-
bearing region of the joint and mounted at 80 μm intervals.  Three slides covering the central 
sections of each joint were stained with Safranin-O and fast green.  A single section representing 
the most severe evidence of arthritic changes was selected for each joint and was scored 
according to a modified Mankin scoring system (40).  Images were randomized and two blinded 
scorers (BAM, RDB) assigned grades, by consensus, to the tibial and femoral cartilage in the 
medial and lateral compartments.  Ordinal scores were assigned for 7 parameters related to 
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degeneration including cartilage structure (score range 0-11), loss of Safranin-O staining (range 
0-8), tidemark duplication (range 0-3), fibrocartilage formation (range 0-2), chondrocyte clones 
in uncalcified cartilage (range 0-2), hypertrophic chondrocytes in calcified cartilage (range 0-2), 
and subchondral bone thickness (range 0-2). Scores were summed for the lateral femur, medial 
femur, lateral tibia, and medial tibia to arrive at a maximum score of 120 for each knee.
Statistics
All statistical analyses were performed using JMP Pro (JMP, Cary, NC).  Continuous, normally 
distributed data (N50%WT, NWB, NLUM) were analyzed by two-way analysis of variance (ANOVA) 
with Tukey post hoc test, treating day and group (MIA, Saline) as factors. Significance was 
tested at α = 0.05.  Ordinal (Mankin score) and non-normally distributed data (serum cytokines) 
were analyzed by a Friedman test.  Post-hoc analysis with Wilcoxon Signed-Rank Tests was 
conducted with a Bonferroni correction of α = 0.008 (0.05/6). 
To test for hypothesized relationships between NF-B activity (NLUM), serum cytokines (IL-6, 
CXCL1, IL-1, MCP-1, IFN-, and IL-10), and pain-related measures (N50%WT, NWB),
multivariate linear regression was performed using both day 3 and day 28 data (all measures 
collected on these days) for both MIA and saline groups.  Significance of the regressions were 
reported with a Bonferroni correction of α = 0.001 (0.05/45). All variables except N50%WT, NWB
were log-transformed (base-10) prior to statistical analysis.
To test for the ability of NF-B activity luminescent imaging and serum cytokine measures to 
account for pain-related sensitivity in the MIA model, N50%WT and NWB were modeled using 
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partial least squares regression to produce a linear model from the log-transformed variables 
NLUM, IL-6, CXCL1, IL-1, MCP-1, IFN-, and IL-10. A threshold for variable influence on 
projection (VIP) was set at 0.8 for inclusion in the final linear model (41).  The VIP parameter is 
a summarizing tool that describes the relative importance of the predictors in order to rank the 
importance of each X in relation to a chosen response variable.  Both VIP and scaled and 
centered regression coefficients are reported for independent variables included in the final 
model.  K-fold cross validation with 6 subsamples was used to calculate Q
2
, an estimate of the 
predictive power of the models.
To test for relationships that were specific to pain phase (early (day3) or late (day28)), additional 
multivariate linear regressions were performed to test for an association of 50% withdrawal 
threshold (N50%WT) with independent variables (NLUM, IL-6, IL-1, and IL-10) at day 3 or 28.  
Significance of the regression was reported with a Bonferroni correction of α = 0.0125 (0.05/4) 
applied for both days 3 and 28. Linear regression was performed to test for an association of 
weight-bearing (NWB) at day 3 or day 28 with independent variables (NLUM, IL-6, CXCL1, and 
MCP-1).  Significance of the regression was reported α = 0.0125 (0.05/4) for both days 3 and 28.
Independent variables were log-transformed (base-10) prior to statistical analysis.
Results
NF-B Activity in MIA
A transient increase in NF-B activity luminescence (NLUM) (~4-5 fold) was observed following 
MIA injection into the knee joint (Figure 1B and C).  Luminescence was observed consistently 
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and broadly distributed in the MIA injected limb on day 1. Over time, the intensity of 
luminescence, which peaked at the knee ROI day 1 post-injection, slowly and steadily declined 
thereafter (Figure 1B). For MIA injected knees, luminescence (NLUM) was significantly increased 
in the knee ROI compared to pre-injection values on days 1 (p<0.0001) and 3 (p<0.0001; 
ANOVA) (Figure 1C), but returned to pre-injection levels by day 28.  Additionally, 
luminescence (NLUM) was significantly increased in MIA injected knees compared to saline 
injected knees on day 3 (p=0.043; ANOVA).  
Ex Vivo NF-B Activity Luminescent Imaging
In vivo luminescence (LUMROI) was significantly correlated to the ex vivo tibiofemoral knee 
luminescence (LUMKNEE) (R
2
= 0.71, p<0.0001), and ex vivo patella luminescence 
(LUMPATELLA) (R
2
= 0.52, p<0.0001), with evidence of weaker correlations to ex vivo muscle 
luminescence (LUMMUSCLE) (R
2
= 0.16, p<0.016) (Figure 2).  This observation confirms the 
tibiofemoral knee as the primary source of in vivo NF- κB generated luminescence.
Serum Cytokines
Serum levels of IL-6 were transiently increased following MIA injection into the knee joint 
(Figure 3).  Serum IL-6 was significantly increased in MIA injected animals compared to saline 
injected animals on day 3 (p=0.004) and significantly increased on day 3 compared to day 28 in 
MIA injected animals (p<0.0001; Friedman Test).  There was no evidence of between group or 
time-related differences in serum cytokines CXCL1, MCP-1, IFN-, IL-1, IL-10 (p > 0.05; 
Friedman Test). 
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Histological Evidence of Arthritis
Histological scoring indicated that MIA injected knees showed the greatest change in 
proteoglycan loss, fibrillation/clefts of the articular cartilage surface, and hypertrophic 
chondrocytes in the calcified cartilage (Figure 4A).  On day 28, there was evidence of 
statistically significant differences in the total modified Mankin score in MIA injected limbs 
compared to saline injected limbs (p=0.005; Friedman Test) (Figure 4B).
Behavioral Assessments
MIA knee injection resulted in the induction of significantly elevated sensitivity to mechanical 
stimuli (allodynia) in the ipsilateral limb (Figure 4 C, D).  Compared to saline injected 
hindlimbs, the 50% withdrawal threshold (N50%WT) normalized to pre-injection values was 
significantly decreased for MIA injected hindlimbs on days 3 (p<0.0001), 7 (p=0.0043), 21 
(p=0.0021), and 28 (p=0.0033; ANOVA), and significantly decreased in MIA injected limbs 
compared to pre-injection levels on days 3 (p<0.0001) and 7 (p<0.0001; ANOVA) (Figure 4C).  
On day 28, MIA injected limbs showed a trend for decreased N50%WT compared to pre-injection 
levels, but failed to reach the threshold for statistical significance (p=0.082; ANOVA).  The
percent of weight-bearing on the ipsilateral limb significantly decreased in MIA injected limbs 
on days 3 (p=0.0002) and 7 (p=0.035; ANOVA) compared to pre-injection values and day 3 
(p=0.023; ANOVA) compared to saline injection (Figure 5D).
Relationships Between NF-B Activity, Serum Cytokines, and Pain-Related Sensitivities
NF-B activity, serum cytokines, and the pain-related sensitivities (Figure 5 and 6) were all 
significantly associated in the MIA model.  After adjusting for multiple comparisons by 
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Bonferroni correction, multivariate linear regression identified a correlation for NF-B activity 
(luminescence) and pain-related sensitivity data when analyzed independently of pain phase (i.e. 
early (day 3) and late (day 28)).  NF-B activity (NLUM) was strongly negatively correlated to the 
50% withdrawal threshold (N50%WT) (r = -0.70, p=<0.0001) (Figure 5). No evidence of 
additional significant correlations was detected between NF-B activity (NLUM), mechanical 
allodynia (N50%WT), weight-bearing (NWB), and serum levels of IL-6, CXCL1, IL-1, MCP-1, 
IFN-, and IL-10 when analyzed independently of pain phase.
A linear model was constructed for mechanical allodynia (N50%WT) and weight-bearing (NWB) 
using the non-invasive measure of NF-B activity (NLUM) and serum cytokines (Figure 6A).  The 
model for mechanical allodynia described ~75% (R
2
) of the variability in mechanical allodynia 
(N50%WT) using the variables NLUM (VIP = 1.7), IL-6 (VIP = 1.3), IL-1 (VIP = 0.8), and IL-10 
(VIP = 0.9).  Using K-fold cross validation the model was able to predict ~67% (Q
2
) of the 
variability in the data.  The model for weight bearing described ~27% (R
2
) of the variability in 
weight bearing (NWB) using the variables NLUM (VIP = 1.6), IL-6 (VIP = 1.3), CXCL1 (VIP = 
1.3), and MCP-1 (VIP = 1.1).  However, using K-fold cross validation the model was able to 
predict only ~7% (Q
2
) of the variability in the data.
Of the significant parameter estimates observed in the general linear model, only NF-B related 
luminescence (NLUM) was significantly correlated to mechanical allodynia (N50%WT) when 
analyzed independently of pain phase (Figure 5).  Multivariate correlations were conducted to 
compare the significant variables in the linear models to mechanical allodynia and weight-
bearing by day.  Adjusting for multiple comparisons, luminescence (NLUM) and the 50% 
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withdrawal threshold (N50%WT) were strongly negatively correlated (r = -0.78, p=0.0029) on day 
3, serum IL-6 and N50%WT were strongly negatively correlated (r=-0.67, p=0.011) on day 3, and 
serum IL-1 and N50%WT were strongly negatively correlated (r=-0.72, p=0.0088) on day 28 
(Figure 6B). NF-B activity (NLUM) and ipsilateral weight-bearing (NWB) were also strongly 
negatively correlated (r=-0.71, p=0.012) on day 3 (Figure 6C).
Discussion
We used luminescent imaging to investigate the relationship between NF-B activity, cytokine 
levels, and pain sensitivities in a rodent model of OA. The tibiofemoral knee appeared to be the 
principal source of NF-κB related luminescence following MIA injection, and revealed strong 
relationships between local measures of NF-κB activity, pain sensitivity, and systemic measures 
of IL-6. These findings establish luminescent imaging of NF-B activity as a novel imaging 
biomarker of pain-related sensitivities in a rodent model of OA. 
Injection of MIA into the NF-B-luc reporter mice produced both histological and behavioral 
changes associated with the development of arthritis (26, 35).  Significant histological changes 
were observed in the MIA injected knees by day 28.  A biphasic pain response was observed 
with an acute increase in mechanical sensitivity followed by a persistent increase in MIA 
injected limbs compared to saline control limbs on days 21 and 28.  Similar biphasic pain 
responses that include an early inflammation associated pain phase and a late non-inflammation 
associated pain phase have been reported in weight bearing and spontaneous mobility in the MIA 
model (36, 37).  Thus, the biphasic response observed in the mechanical sensitivity data is 
consistent with these previous pain-related behavioral measures.  
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The biphasic response has been reported in the rat model at moderate MIA injection 
concentrations (6 – 60 mg/ml) (36, 37), while high concentrations (50-100 mg/ml) produce a 
pain response that is characterized by rapid onset, no recovery, and is sustained chronically in 
both mice and rats (33, 44, 45).  The concentration used within this study (10 mg/ml) was within 
the range expected to produce a biphasic pain response.   It is important to note that, while 
present, the late pain phase observed in this study was moderate and was only observed in the 
mechanical allodynia measure.  A more severe chronic pain response in both mechanical 
allodynia and weight bearing would have likely been observed at higher concentrations of MIA 
injection. 
Luminescent in vivo imaging provides a powerful tool to non-invasively quantify molecular 
events during musculoskeletal disease progression and therapeutic intervention. NF-B activity 
was observed in the ex vivo tibiofemoral knee and patella with a strong correlation with the in 
vivo ROI luminescence measurements.  The ex vivo imaging established the tibiofemoral knee, 
and to a lesser extent the patella, as the sources of the in vivo total knee ROI luminescence.  In 
vivo luminescent imaging as used here, provided a spatially accurate measure of NF-B activity 
in the knee that may be useful for the rapid screening of NF-B targeting therapeutics for the 
treatment of OA and other inflammatory pathologies (18, 42).
MIA injection induced a transient increase in NF-B activity that preceded histological changes 
in the knee.  Immediately post injection, elevated NF-B activity was observed throughout the 
limb on day 1, which localized to the knee by day 3, and returned to pre-injection levels by day 
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28.  This pattern was consistent with the pattern previously reported for MIA injection, namely 
an inflammatory response in the first 1-3 days post-injection, followed by a subsequent 
dissipation of inflammation (29, 30). Additionally, NF-B activity has been demonstrated 
during inflammation in models of collagen-induced and adjuvant-induced arthritis (28, 43).  A 
peak in joint swelling at day 1, a peak in synovial hyperplasia at day 3, and synovial 
inflammatory cell invasion characterizes this inflammatory response through day 3 in the MIA 
model.  It is possible that the day 3 time point chosen for this study may have missed the peak 
levels of inflammation and pain sensitivity, but the elevated NF-κB activity/IL-6 levels at day 3 
indicate that this time point falls within the inflammatory period of this model.  Our data suggest 
that the primary role of NF-B in the MIA model is as a mediator of the early inflammatory 
response and may suggest that NF-B targeted therapeutics would be most effective during the 
early developmental phases of OA.
In this study, luminescent imaging of NF-B activity and NF-B regulated serum cytokines were 
validated as biomarkers of pain-related sensitivities in the MIA model.  NF-B activity was very 
strongly correlated to mechanical allodynia and was the only measure with significant correlation 
to mechanical allodynia when analyzed independently of pain phase.  A linear model was 
constructed that was capable of predicting ~67% (Q
2
) of the variability in the mechanical 
allodynia data, which included luminescent imaging of NF-B activity, serum IL-6, serum IL-1β, 
and serum IL-10 as predictive variables. NF-B activity was determined as the most important 
variable in the model according to VIP. When these measures were correlated to mechanical 
allodynia by pain phase, NF-B activity and serum IL-6 were strongly correlated to mechanical 
sensitivities in the early pain phase and IL-1β was strongly correlated to mechanical sensitivities 
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in the late pain phase. These data support the presence of an early inflammatory pain phase and a 
late non-inflammatory pain phase in the MIA model of OA and suggests distinct biomarkers can 
distinguish the two phases.  It may indicate a distinct role for the NF-B /IL-6 pathway in the 
acute pain sensitivities in arthritis and IL-1β in chronic pain sensitivities associated with 
joint/cartilage destruction.   This is consistent with previous findings that both IL-6 and IL-1β are 
associated with increased pain sensitivities in the rodent knee joint (7, 46).  Overall, the 
luminescent imaging of NF-κB activity and serum cytokine measures suggest utility as a panel of 
non-invasive biomarkers of pain-related sensitivities in the MIA model with biomarker subsets 
unique for distinguishing the distinct pain phases.  
This study demonstrates the use of non-invasive in vivo luminescent imaging to measure NF-кB 
activity in a mouse model of osteoarthritis and the comparison of key molecular events in 
arthritis to pain sensitivity development. MIA injection induced a transient increase in NF-кB 
activity at early time points in the tibiofemoral joint, which was correlated with developing pain 
sensitivities in this model of OA. NF-кB activity and serum IL-6 were specifically related to the 
inflammation-associated acute pain phase and IL-1β with the late pain phase following MIA 
injection.  The demonstrated relationship between NF-кB activity, a subset of serum cytokines 
(i.e. IL-6, IL-1β, and IL-10), and mechanical allodynia suggests the use of NF-кB luminescent 
imaging with serum cytokines as non-invasive biomarkers of pain sensitivities in this model.  It 
will be important in future work to test how these results translate to human OA and it is 
important to note that the transgenic nature of the luminescent imaging of NF-κB activity makes 
this imaging a challenge in the clinical setting.  These data suggest the feasibility and utility of 
19
luminescent imaging of NF-κB for rapid screening of targeted NF-κB antagonists for treating 
knee OA and other pathologies driven by NF-κB.
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Figure 1 – (A.) Selection of knee ROI based on (i.) radiograph, (ii.) and reflected light image 
showing (iii.) overlay of ROI upon luminescence image of mouse limb. (B.) In vivo imaging of 
NF-B activity in MIA and saline injected knees over 28 days.  (C.) Quantitative fold-change in 
knee ROI luminescence (NLUM) compared to preoperative levels over 28 days. (p<0.05, 
significance noted compared to preop (#) or saline (*))
27
Figure	2 – (A.)	Ex	vivo luminescence	imaging	of	ipsilateral	and	contralateral	knee	joint,	
patella,	and	adjacent	muscle	tissue	with	linear	correlation	coefficients	to	in	vivo knee	ROI	
luminescence	(LUMROI)	(p-values	for	correlations	in	parenthesis).	(B.)	Linear	correlation	
between	in	vivo knee	ROI	luminescence	(LUMROI)	and	ex	vivo knee	luminescence	(LUMKNEE).
28
Figure	3 – Serum	cytokine	levels	for	IL-6,	CXCL1,	MCP-1,	IFN-,	IL-1,	and	IL-10	on	day	3	
and	28	for	MIA	and	saline	groups.		(p<0.05,	significance	noted	between	all	groups	(*)	for	IL-
6	only)
29
Figure	4 – (A)	Representative	Safranin-O/fast	green	stained	histological	sections	and	(B)	
total	Mankin	score	from	saline	and	MIA	injected	limbs	on	day	3	and	28	(p<0.05, Friedman 
test, significance noted compared saline (*)).	(C)	Normalized	measures	of	mechanical	
allodynia	(N50%WT)	and	(D)	weight	bearing	(NWB)	in	the	ipsilateral	limb	for	MIA	and	saline	
groups	over	28	days.	(p<0.05, two-way ANOVA, significance noted compared to preop (#) and 
saline (*)).
30
Figure	5 –50%	withdrawal	threshold	(N50%WT)	plotted	against	NF-B	activity	(LUMROI)	for	
the	ipsilateral	limb	at	all	time	points	(Preop	and	days	3,	7,	14,	21,	and	28).	
31
Figure	6	– (A.)	Partial	least	squares	(PLS)	linear	regression	models	created	for	mechanical	
allodynia	(N50%WT)	and	weight	bearing	(NWB).		Multivariate	linear	correlations	for	variables	
in	respective	PLS	linear	model	to	(B.)	mechanical	allodynia	and	(C.)	weight-bearing	by	day.	
(significant	correlations	denoted	by	*)
